Sodium glucose co-transporter-2 inhibitors have attracted the interest of the scientific community following the results from dedicated cardiovascular outcome trials, which demonstrated remarkable reduction in all-cause mortality and other cardiovascular (CV) endpoints with empagliflozin and canagliflozin. These impressive results raised further expectations on real world data from large observational cohort studies. They were designed to address the possible existence of a class effect, and the uncertainty on whether this benefit can be extended from secondary to primary CV prevention of patients with type 2 diabetes. In this review, we collated data from existing observational studies (including the celebrated CVD-REAL cohorts) and critically appraised results and methodological issues with the aim of providing clinical insight, including unsettled aspects, and proposing a research agenda for future investigations. Findings from the EMPA-REG OUTCOME trial (empagliflozin) and the CANVAS trial programme (canagliflozin) have demonstrated significantly (14%) reduced MACE (a composite of death from CV causes, non-fatal myocardial infarction, or non-fatal stroke), with a remarkable 32% reduction in all-cause mortality in EMPA-REG Outcome. 4,5 Significant renal benefits were also found in both trials, although outcome definitions were dissimilar, thus making direct comparisons not appropriate. Notwithstanding these impressive results, several unresolved issues arose in this medication class. In particular, two issues remain: (1) the possible existence of a class effect, and (2) the uncertainty on whether this benefit can be extended from secondary to primary CV prevention, that is, if it may apply to all patients with type 2 diabetes mellitus (T2DM).
1 This is going to change the clinical mission of diabetologists from treat to target to treat to benefit and is capturing the interest of general practitioners and cardiologists, 2 with a number of recently conducted or ongoing CVOTs for various antidiabetic medications, including SGLT2-Is. 3 Findings from the EMPA-REG OUTCOME trial (empagliflozin) and the CANVAS trial programme (canagliflozin) have demonstrated significantly (14%) reduced MACE (a composite of death from CV causes, non-fatal myocardial infarction, or non-fatal stroke), with a remarkable 32% reduction in all-cause mortality in EMPA-REG Outcome. 4, 5 Significant renal benefits were also found in both trials, although outcome definitions were dissimilar, thus making direct comparisons not appropriate. Notwithstanding these impressive results, several unresolved issues arose in this medication class. In particular, two issues remain: (1) the possible existence of a class effect, and (2) the uncertainty on whether this benefit can be extended from secondary to primary CV prevention, that is, if it may apply to all patients with type 2 diabetes mellitus (T2DM).
Within this scenario, a number of observational studies on longitudinal healthcare databases were published outside the stringent environment of CVOTs in order to test the actual effectiveness in the socalled real-world evidence (RWE) area. While RWE indicates that the evidence is obtained from the analysis of real-world data (RWD), the term RWD is rather new, and there is considerable variability in its definition: in general, the term RWD is used to define data collected outside randomized controlled trial (RCT) settings, although other definitions diverge from this concept. 6 In the wake of this debate on terminology, we support the use of the term pharmaco-epidemiological research (PER) to describe the clinical setting of observational analysis.
While most opinions converge in considering PER a complementary source of evidence as compared to RCT, it is important to underline that PERs are definitely different from RCTs and have distinct inherent limitations: RCTs do not measure the benefit in clinical practice (low external validity), despite attempting to be pragmatic (e.g. by enrolling patients with T2DM at high CV risk), whereas PERs do not prove causal-effect relationships despite being pragmatically cogent (enrolling a broad and diverse population in clinical practice); thus, their integration offers substantial synergy for risk-benefit assessment and final determination of the place in therapy. 7, 8 Stakeholders are discussing if and how PERs can be a substitute for RCTs and be exploited to support regulatory decision-making: the challenging issue for researchers in increasing validity and reliance on PER (i.e. clinical transferability) is to avoid common flaws in design, balancing measured and unmeasured confounders, conducting sensitivity analyses, and clearly reporting methods and findings. 9 In this review, we will appraise eight PER studies recently conducted through a cohort design on the CV benefit of SGLT2-Is in order to (1) provide a summary of results with relevant clinical implications, and (2) propose a research agenda for unsettled issues.
| OVERVIEW OF RESULTS

| CVOTs: beyond cardiovascular protection
Impressive findings emerged for CV outcomes from the two CVOTs, including potential renal protective effects. In particular, the EMPA-REG Outcome study showed 38% reduction (hazard ratio patients newly initiated on SGLT2-Is versus other glucose-lowering drugs. Notably, these patients were not at increased CV risk (only 13% had established CV disease). In this propensity-matched PER using data from medical claims, primary care/hospital records, and national registries in six countries (the United States, Germany, Sweden, Norway, Denmark and the UK), the authors assessed the risks of hospitalization for heart failure (HHF), death, and the combined endpoint of heart failure hospitalization or death, which were all lower in patients receiving an SGLT2-I, without significant heterogeneity across countries and with consistent results among multiple sensitivity analyses. 10 In particular, the pooled analysis of all-cause death using patient data from five of the countries (this information was not available for the German registry) showed a 51% reduction favouring patients with SGLT2-Is (0.49; 0.41-0.57; without significant heterogeneity among SGLT2-Is).
Overall, the CVD-REAL study did not examine other hard endpoints, such as MACE (cardiovascular death, myocardial infarction and stoke), which were not available in all cohorts. The CVD-REAL Nordic sub-study examined CV mortality in patients from Sweden, Denmark and Norway (where detailed national registries allowed assessment of the cause of death). Among SGLT2-Is, dapagliflozin accounted for 94% of the total SGLT2-I exposure time. Over a median follow-up of 0.9 years, the study showed that CV mortality was reduced by 47% in patients newly initiated on an SGLT2-I compared with other glucoselowering medications (0.53; 0.40-0.70). 11 The CVD-REAL Nordic was the only study examining CV mortality, which was also reduced independently of CV disease at baseline. A further sub-analysis of the CVD-REAL Nordic database found that patients newly initiated on dapagliflozin experienced a lower rate of CV events, HHF and allcause mortality compared with patients newly initiated on DPP4
inhibitors. 12 It appears that the CV benefit was mainly driven by Danish data, whereas the Norwegian cohort was not associated with statistically significant reduction of CV mortality and MACE.
The recent CVD-REAL 2 was designed to cover a large proportion of patients residing outside the United States and Europe and to address uncertain aspects such as the risk of stroke (being more common in Asia and previously found to be non-significantly increased in the EMPA REG Outcome trial considering that US data in the CVD-REAL study largely contributed to study findings, and that the Nordic sub-study exploited data from Sweden.
The latest OBSERVE-4D directly compared SGLT2-Is for safety and effectiveness: statistically significant differences did not emerge among gliflozins in terms of HHF and atraumatic below-knee lower extremity amputations (BKAs), but meta-analytic estimates showed reduced risk of HHF when comparing canagliflozin or other SGLT2-Is versus non-SGLT2-Is, with no increased risk of BKAs. 24 The strengths of these real-world cohorts are mainly represented by the catchment area (virtually worldwide with millions of patients)
accounting for the high heterogeneity seen in the diabetic population.
Moreover, the propensity-score matching adopted in many studies considered hundreds of covariates to minimize the effect of known confounders. Notably, the results were directionally consistent within and across databases, countries, patient subgroups (including those w/wo CV disease), type of SGLT2-I and comparators (insulin, sulphonylureas, thiazolidinediones, incretin-based therapies). Notably, only in the EASEL and CVD-REAL Nordic studies were age and sex tested as subgroups: significant differences emerged only for CV mortality and MACE in patients <65 years (neutral association). In other cohorts, age and sex were only used as matching variables in the propensity score comparison and as covariates to adjust HRs in multivariate survival analyses.
3 | A CRITICAL APPRAISAL OF METHODOLOGICAL ISSUES
| Administrative claims databases: validity first
Limitations of PER cannot be disregarded and typically stem from the observational nature of the data; outcome data were not collected in a systematic fashion and events of interest were not adjudicated by an independent committee; in routine clinical practice, the primary diagnoses of admission or discharge are based on the opinion of physicians, and may be influenced by reimbursement policies.
Both diabetes and CV diagnoses in claims administrative databases are challenging and the positive predictive values of the adopted algorithm may vary among data sources. Therefore, before pooling data through meta-analysis (MA), validity remains a crucial aspect of study design and conception. [25] [26] [27] [28] In particular, validation of the diagnoses is critical in the diabetes area, especially when in multinational epidemiological studies, 29 because the lack of clinical data may compromise optimal algorithms for patients' and outcomes' identification. In addition, administrative claims databases do not allow clinical variables associated with CV risk to be fully captured (or they are only available for a subset of the cohort), such as HbA1c, body mass index, lipid levels, and renal function based on creatinine values (instead of being codified as chronic kidney disease stage).
Although the observational studies on SGLT2-Is exploited validated healthcare databases for PER, relevant peculiarities in data registration should not be disregarded. Notably, mortality rate with SGLT2-Is in the CVD-REAL study is much lower than that in the Swedish study (5.2 vs. 25.6 per 1000 person-years, respectively), and the mortality rates in the CVD-REAL study are surprisingly highly variable (from the US cohort's rate of 3.1/1000 per year to the Danish cohort's 18.7/1000 per year), thus potentially reflecting some incompleteness in recording death information in the US database.
| Data analysis: the threat of bias and unmeasured confounders
In the recent past, several methodological challenges have been described in observational studies assessing glucose-lowering medications and CV outcomes, with the majority of publications not adequately addressing appropriate minimization strategies. 30, 31 Causal inference from observational research is challenging to be claimed with certainty, and many associations are likely to be the result of residual confounders. In general, for cohort studies, the threshold of potential interest (confidence) for decreased risk has been suggested to start at 0.33 (effect estimates), whereas a risk estimate of 0.5
should be considered in the so-called zone of potential bias. 32 The majority of data from cohort studies on SGLT2-Is lies in this uncertain zone.
Published PERs on SGLT2-Is adopt a propensity score-matched approach, which is increasingly being used in observational studies of cardiovascular interventions as an alternative to conventional covariate adjustment. A propensity score is defined as the probability of a patient being assigned to an intervention, given a set of covariates and all patient characteristics being summarized into a single covariate, thus reducing (although not eliminating) the potential for overfitting and correcting for selection biases and potential confounding.
While this technique provides an excellent balance of covariates in most circumstances, it is less precise, and some patients may remain unmatched and hence excluded from the analysis. 33 Moreover, it balances the distribution of characteristics between the compared exposure groups on average, thus there may be pairs that are discordant on special characteristics; finally, there is no clear understanding of the relative performance of matching strategies in subgroup analyses. 34 The propensity score cannot account for unmeasured confounders such as the healthier behaviour of patients prescribed a new medication, or the profiles of treating clinicians and their early confidence in a new effective drug. In this regard, quasi-experimental methods using instrumental variables (e.g. local variations in prescribing rates) have been proposed to account for selection bias. 35 A recent cohort study, using a US commercial insurance database, achieved balance in clinical variables, thus minimizing the likelihood of residual confounding (provided that an appropriate comparator, newuser design and 1:1 propensity score matching on many proxies of diabetes severity and duration are considered). 
| CLINICAL INSIGHT INTO OBSERVATIONAL RESEARCH
Overall, the different population-based studies, and especially CVD-REAL cohorts, confirmed the efficacy emerging from the EMPA-REG Outcome and CANVAS programme in terms of MACE, all-cause mortality, single CV outcomes and HHF reduction, and also extended the CV benefit to myocardial infarction and stroke. Notably, the recently revised US guideline by the American Diabetes Association considers CV risk when choosing the second-line agent after metformin in patients with T2DM: in this scenario, the guideline specifically recommends an agent proven to reduce MACE and CV mortality in patients with established atherosclerotic CV diseases (currently empagliflozin and liraglutide), after considering drug-specific and patient factors (level of the evidence A). 38 While the results are outstanding from a statistical viewpoint and the relative risk reduction is noteworthy, relevant implications for clinicians may not be obvious and substantiated, especially when communicating and sharing data with patients. In this regard, incidence rates and, most importantly, the number needed to treat to benefit (NNTB), as well the number needed to treat to harm (NNTH), are epidemiological measures of risk that best describe the effect observed in the individual patient.
In Table 2 , we report the incidence rates (in published population- (6) overall, it appears that the NNTBs are roughly comparable with those derived from the UKPDS follow-up 42 (in the metformin group comparing intensive vs. conventional therapy, the NNTB for the endpoint death from any cause was 139).
| OBSERVATIONAL FINDINGS: WHAT'S MISSING?
| The knowledge gap on effectiveness
The research agenda still faces some unsettled issues concerning prescribing and optimal management of patients with T2DM, namely:
what knowledge gaps are still outstanding after CVD-REAL studies?
What type of evidence is required to best meet this clinical need?
In terms of effectiveness, there is interest in verifying whether pharmacological modulation with SGLT2-Is could be part of the armamentarium for treating patients with heart failure, with and without diabetes. 43 Intriguingly, different large RCTs are ongoing (EMPERORPreserved, EMPEROR-Reduced, DAPA-HF), which do not include diagnosis of T2DM in the inclusion criteria. 44 Clinicians might also wonder whether or not clinically significant differences exist among SGLT2-Is through head-to-head comparative research. As discussed below, it appears that the existence of specific effects is a matter of safety rather than an efficacy issue, with the OBSERVE-4D MA of four US databases showing no difference in the estimates of HHF and BKAs. 24 In the modern era, cost-effectiveness analyses are also awaited to actually quantify patient's benefit in terms of Quality Adjusted Life Years, and define the therapeutic gain of an integrated management of patients with T2DM.
A fundamental issue regarding the benefit on renal outcomes observed in CVOTs must be confirmed in clinical practice, where different factors may modify and impact the effect of antidiabetic drugs.
None of the CVD-REAL studies and other cohorts have addressed this issue. Data from CVOTs, including a prespecified analysis of renal outcomes in the EMPA-REG Outcome trial, are promising in terms of long-term cardio-renal protection: empagliflozin was associated with a slower progression of kidney disease and lower rates of clinically relevant renal events. 45 However, subjects with chronic kidney disease (eGFR <30 mL/min/1.73 m 2 ) were excluded from both the CANVAS and EMPA-REG Outcome trials, with relevant contraindication in patients with moderate to severe renal impairment. 46 Conversely, scattered reports suggest that there might be a risk for short-term acute kidney injury, usually in the form of a reversible reduction of GFR, but may occasionally be fatal or require renal replacement therapy, 47 with potential differences among compounds. 48 Warnings of an increased risk of early-onset kidney injury were therefore strengthened by the FDA on the labels of SGLT2-Is, with the latest postmarketing data from the FDA Adverse Event Reporting System confirming a potential signal for acute kidney injury with all approved SGLT2-Is. 49 This effect may be attributed to different mechanisms, including natriuresis and osmotic diuresis-induced hypovolemia, as well as renal haemodynamic effects, mediated by adenosine and increased glucagon, resulting in vasoconstriction of afferent arterioles.
Drugs causing vasodilation of the efferent arterioles (namely reninangiotensin-aldosterone system blockers) might synergistically act with SGLT2-Is in acute eGFR reduction, which may become clinically relevant in subjects with underlying extracellular volume depletion, Table 1 for the definition of MACE, which in this case was defined as incident cardiovascular disease).
that is, those treated with diuretics or receiving non-steroidal antiinflammatory drugs, giving rise to a new pattern of the clinical entity known as triple whammy.
| Debated safety issues
There are different uncertainties as regards the risk of BKAs, bone fractures, infections and ketoacidosis, which were not scrutinized in CVD-REAL studies. Genital and urinary tract infections were associated with all members of the class and predictable on the basis of the mechanism of action; although the true rate in clinical practice is still uncertain, the high reporting frequency in the postmarketing phase calls for real-time pharmacovigilance monitoring. 50 The overall evidence suggests that SGLT2-Is increase the risk of genital mycotic infections by four to five times according to the largest MA, 51 although they are usually mild to moderate, can be adequately treated with standard medical therapy, and drug discontinuation is not [16] CVD-REAL Nordic [12] EASEL [14] CVD-REAL 2 [13] US Cohort [15] Total (95% CI) Total events Heterogeneity: Tau2 = 0.01; Chi2 = 19.36, df = 6 (P = 0.004); I2 = 69% Test for overall effect: Z = 9.98 (P < 0.00001) [14] CVD-REAL Nordic [12] CVD-REAL [10] US cohort [15] CVD-REAL 2 [13] Total (95% CI) Total events Heterogeneity: Tau2 = 0.10; Chi2 = 166.49, df = 5 (P < 0.00001); I2 = 97% Test for overall effect: Z = 3.61 (P = 0.0003) FIGURE 1 Forest plots comparing SGLT2-Is with non-SGLT2-Is for key cardiovascular outcomes. *MACE, major adverse cardiovascular event (this definition may vary among studies); ACM, all-cause mortality; HHF, hospitalization for heart failure. Please refer to individual studies for details. Meta-analysis was performed through RevMan 5.3. Crude numbers were extracted from individual studies and computed using the Mantel-Haenszel method (random effect model); therefore, odds ratios of the individual studies may differ compared with published estimates. Where available, data on intention-to-treat population at low cardiovascular risk were used. Comparator (non-SGLT2-Is) can be represented by all other antidiabetics, insulin or DPP4, depending on studies. The US cohort and OBSERVE-4D study were the only ones on canagliflozin. Data on the CVD-REAL Nordic and Swedish cohort studies are derived from the dapagliflozin dataset in RCTs (in line with data from an MA 54 ) and 1.6/1000 person-years in cohort studies. In case reports and in pharmacovigilance databases, duration of SGLT2-I treatment before DKA onset was extremely variable; overall, DKA is a rare adverse event during SGLT2-I therapy, with fatal episodes representing 1.6% of all reported cases. 55 The lat- 6 | OBSERVATIONAL RESEARCH: WHAT IS NEXT?
| Avoiding redundant meta-analyses
From a research perspective, systematic reviews with MA are traditionally performed following the availability of evidence from RCTs and PERs, although the pressure for publication and the general perception of a free-from-bias evidence-based study may generate massive production of unnecessary (redundant) research.
68-70
The case of SGLT2-Is is not an exception: several MAs of RCTs are accruing, 71 with expected overlapping conclusions on CV benefit (especially when also pooling data from CVOTs), 41 whereas, to the best of our knowledge, no MA has specifically been carried out on observational studies for SGLT2-Is.
MAs are strongly encouraged when individual studies are conflicting, estimates are large and uncertain, or there are some topics not addressed by individual studies. Therefore, we do not believe that an MA of observational studies on CV outcomes per se would add clinically important evidence to the existing SGLT2-Is data: cohort studies provided consistent data on CV risk reduction for almost all endpoints (the directions of the estimates are reliable and robust across and within cohorts/subpopulations/sensitivity analyses). Thus, as expected, pooling of these data would confirm the robustness of the findings from single studies despite failing to draw firm conclusions because of high heterogeneity (Figure 1) . Apart from the limitations of this statistical exercise (no systematic reviews were performed, outcomes overlap only partially, and neither quality nor subgroup analyses were carried out), the statistical and clinical heterogeneity of the studies might hamper the existence of a drug-related clinically significant CV benefit.
| The added value of informative meta-analysis
A novel informative MA should assess renal outcomes such as progression to albuminuria or serious decline in renal function, unquantified outcomes (infections), and debated issues such as BKAs or fractures. 72 From a methodological viewpoint, individual patient-data MAs and head-to-head RWD from observational studies could represent a viable research option, such as the OBSERVE-4D meta-analytic approach.
24
Network meta-analyses (NMAs) are increasingly prevalent in medical journals, and capture the interest of clinicians and policymakers as they provide two types of findings for a specific outcome:
the relative treatment effect for all pairwise comparisons (direct and indirect evidence), and a ranking of the treatments. However, the challenges and pitfalls of these statistical approaches must be carefully considered. In the diabetes area, the first NMA by Zaccardi et al. assessed cardio-metabolic and safety outcomes of 38 RCTs comparing SGLT2-Is with placebo, also providing indirect comparisons among the three drugs; the authors found that all SGLT2-Is increased risk of infections to a similar extent, whereas canagliflozin 300 mg performed better in terms of efficacy than the other inhibitors. 73 Recently, an NMA of RCTs compared the efficacy of SGLT2-Is, GLP-1 receptor agonists and DPP4 inhibitors for mortality and CV endpoints, and concluded that SGLT2-Is ranked first in terms of CV mortality. 74 This systematic review with an NMA has several strengths and followed current standards for reporting and conducting meta-analytical studies. 75, 76 However, clinicians should be advised that focusing on the probability of being ranked first is potentially misleading. In particular, comparisons between SGLT2-Is and GLP-1 receptor agonists or DPP4
inhibitors suffer from both qualitative and quantitative drawbacks, thus making any firm conclusion decidedly premature (Table 3 ).
| SUMMARY AND CONCLUSION
Landmark CVOTs with SGLT2-Is have generated a paradigm shift in the management of patients with T2DM, specifically in those with prior macrovascular disease, with a transition from past algorithms based primarily on glucose and HbA1c control to a more comprehensive strategy focused on CV prevention. This possible benefit was acknowledged by the FDA, which added a new indication to Stroke/MI FIGURE 2 Current evidence on the evolving risk-benefit evaluation of SGLT2-Is, with ongoing cardiovascular outcomes trials (CVOTs) potentially affecting final assessment. ACM, all-cause mortality; GTIs, genital tract infections; HHF, hospitalization for heart failure; MACE, major adverse cardiovascular events; MI, myocardial infarction; NAFLD, non-alcoholic fatty liver disease; UTIs, urinary tract infections. Colour coding: green = CONSOLIDATED EVIDENCE (general agreement among types of evidence †); blue = ENCOURAGING EVIDENCE (partial agreement among types of evidence †); orange = PRELIMINARY EVIDENCE (incomplete/pending data, only from a single type of evidence, namely CVOTs); and red = UNCERTAIN EVIDENCE (conflicting data among types of evidence †).
† Including systematic reviews with meta-analyses, clinical trials, observational and pharmacovigilance studies empagliflozin, and is now partially recognized by the 2018 American Diabetes Association guideline, thus increasing the competition to identify the optimal glucose-lowering combination.
Large PER studies such CVD-REALs should be commended for advancing knowledge by pooling such large amounts of prescription data and providing data on heterogeneous cohorts of patients with T2DM. Overall, data from observational cohort studies are not only in agreement with those from RCTs, but also found a larger benefit compared with CVOTs in a population with lower CV risk. Notwithstanding these impressive results and sophisticated statistical techniques,
we cannot yet firmly conclude that there is a class effect, and uncertainty remains on safety issues in particular, including BKAs, infections, fractures and renal effects (Figure 2 ). In essence, confounders were largely minimized through propensity analysis, whereas immortal time bias and time-lag bias were not fully accounted for in CVD-REAL studies. 18, 21 The heterogeneity of cohorts stresses the importance of assessing patients for comparability before data pooling. We believe that the strength of CVD-REAL studies lies not in their ability to merge worldwide data, but in capturing the specificities of prescription patterns. In other words, data from a single database should be 
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